First line treatment of small cell lung cancer with keytruda chemotherapy significantly improves PFS

On January 7, MSD announced that keytruda, a heavy-duty PD-1 inhibitor, was used in combination with chemotherapy to significantly improve the primary end point of progression free survival (PFS) in phase 3 clinical trials of first-line treatment of extensive small cell lung cancer (es-sclc) In this study, keytruda combined with etoposide, cisplatin or carboplatin reduced the risk of disease progression or death by 25% compared with chemotherapy (HR = 0.75, 95% CI, 0.61-0.91) Lung cancer is the leading cause of cancer death in the world Small cell lung cancer accounts for 10-15% of total lung cancer The 5-year survival rate of SCLC patients in the United States is only 6% A randomized, double-blind, placebo-controlled phase 3 trial named keynote-604 included 453 es-sclc patients The trial had a double primary end point, PFS and total survival time (OS) Keytruda and chemotherapy combination significantly improved the primary end point of PFS At the same time, this combination therapy improved the overall survival of patients compared with chemotherapy, but the OS results did not reach the statistical significant level (HR = 0.80, 95% CI, 0.64-0.98) "The trial results of keynote-604 show that keytruda combined with chemotherapy has the potential to improve the treatment results of patients with primary es-sclc It's a very aggressive cancer, "said Dr Roy Baynes, chief medical officer of the MSD research laboratory." we sincerely thank the patients and researchers who participated in this study " reference material: A kind of